By Josh Beckerman
Sarepta Therapeutics exceeded 2024 net product revenue guidance and reaffirmed its 2025 outlook, partly due to strong growth for Duchenne muscular dystrophy drug Elevidys.
The company reported preliminary 2024 net product revenue of $1.79 billion, exceeding full-year guidance by over $100 million. This was up about 56% from 2023. For 2025, it expects net product revenue of $2.9 billion to $3.1 billion.
Sarepta had preliminary cash, cash equivalents, restricted cash and investments of about $1.5 billion as of Dec. 31.
The company will report complete results in late February.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 13, 2025 13:00 ET (18:00 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。